2024 marked a pivotal change in the management of asthma in the UK with the publication of a joint British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guideline.
The resource is a current resource and has been published or reviewed within the last three years
As a summary, this policy statement advocates:
In this inspiring article we learn about the power of storytelling for children and young people suffering from asthma. Asthma is a very common disease, and for some it is a lifelong condition requiring long-term self-management.
In a time of uncertainty and financial pressure, this issue of Primary Care Respiratory Update (PCRU) is a vital resource for anyone working in respiratory care. As Integrated Care Boards across England face significant budget cuts, programmes that have taken years to build are now under threat.
Single-use vapes are now banned from the shelves of all shops (from Sunday 1 June) thanks to a government blitz on sale and supply.
With the landmark Tobacco and Vapes Billentering its final stages in Parliament, and just days before World No Tobacco Day (31 May)and the nationwide ban on disposable vapes (1 June 2025),
For our next In Conversation Katherine was joined by Dr Richard Russell, a man of many respiratory interested hats!
This is the second webinar in the PCRS Maintenance and Reliever Therapy (MART) in asthma campaign.
In November 2024 NICE, in collaboration the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN), released guidance NG245.
In this podcast Fiona Mosgrove (PCRS Education lead) and Tom Fardon (Consultant Physician) discuss asthma biologics and how they can support effective severe asthma care.
In November 2024 the National Institute for Health and Care Excellence (NICE), in collaboration with the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN), launched their updated guideline: Asthma: diagnosis, monitoring and chronic asthma
Are you struggling to persuade your Integrated Care Board (ICB) to fund FeNO testing? With the new BTS/NICE/SIGN asthma guideline recommending FeNO for asthma diagnostic testing, this can create quite a challenging for primary care providers.
The Medicines and Healthcare products Regulatory Agency (MHRA) has put out a reminder for healthcare professionals and patients with asthma that overuse of blue inhalers (short-acting beta 2 agonists or SABAs), without use of a preventer inhaler, may lead to worsening symptoms or serious asthma a
Childhood asthma is the most common chronic disease in childhood, with a prevalence of 10.2% in 2018. However, there is evidence of over-and under diagnosis in about 30% in mixed populations of adults and children and young people (CYP).